Strongbridge Biopharma plcFind Ratings Reports
STRONGBRIDGE BIOPHARMA PLC's gross profit margin for the second quarter of its fiscal year 2021 is essentially unchanged when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the subsector when comparing revenue growth, but not when comparing net income growth. STRONGBRIDGE BIOPHARMA PLC is extremely liquid. Currently, the Quick Ratio is 2.88 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.
During the same period, stockholders' equity ("net worth") has decreased by 7.26% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY21||Q2 FY20|
|Net Sales ($mil)||10.04||7.76|
|Net Income ($mil)||-13.24||-17.27|
|Balance Sheet||Q2 FY21||Q2 FY20|
|Cash & Equiv. ($mil)||63.77||59.91|
|Total Assets ($mil)||96.82||97.63|
|Total Debt ($mil)||18.15||8.37|
|Profitability||Q2 FY21||Q2 FY20|
|Gross Profit Margin||95.57||95.22|
|Return on Assets||-41.47||-54.01|
|Return on Equity||-90.47||-110.18|
|Debt||Q2 FY21||Q2 FY20|
|Share Data||Q2 FY21||Q2 FY20|
|Shares outstanding (mil)||67.72||54.36|
|Div / share||0.0||0.0|
|Book value / share||0.66||0.88|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||318633.0||1186632.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. To use another comparison, its price-to-book ratio of 3.05 indicates a discount versus the S&P 500 average of 4.51 and a significant discount versus the subsector average of 9.50. The price-to-sales ratio is well above the S&P 500 average, but well below the subsector average. After reviewing these and other key valuation criteria, STRONGBRIDGE BIOPHARMA PLC proves to trade at a discount to investment alternatives.
|SBBP NM||Peers 30.06||SBBP NM||Peers 19.28|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
SBBP's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
SBBP's P/CF is negative making the measure meaningless.
|SBBP NM||Peers 16.22||SBBP NA||Peers 0.53|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
SBBP's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|SBBP 3.05||Peers 9.50||SBBP 27.89||Peers -85.95|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
SBBP is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
SBBP is expected to have an earnings growth rate that significantly exceeds its peers.
|SBBP 3.90||Peers 9.21||SBBP 34.97||Peers 25.27|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
SBBP is trading at a significant discount to its subsector on this measurement.
Higher. A sales growth rate that exceeds the subsector implies that a company is gaining market share.
SBBP has a sales growth rate that significantly exceeds its peers.